Abstract Psoriasis is a common inflammatory cutaneous disease that affects approximately 120 million people worldwide. Systemic treatments have significantly improved disease burden, but concerns persist regarding their association with increased risk of malignancy. Patients with psoriasis have a slightly elevated baseline risk of lymphoproliferative diseases. Studies on methotrexate and cyclosporine, as well as older biological agents such as tumor necrosis factor inhibitors, have found no increased risk of non-cutaneous solid tumors; however, positive associations between cutaneous squamous cell carcinomas and certain therapies have been found. There is conflicting evidence regarding the risk of lymphoma and melanoma. Further studies are needed to determine the long-term safety of newer psoriasis treatments (interleukin [IL]-12/ 23, IL-17, Janus kinase 1/3, and phosphodiesterase-4 inhibitors), specifically their safety in patients with a history of cancer. This review summarizes the most recent studies on malignancy risk from psoriasis, and its treatments in patients and cancer survivors, with the highest available level of evidence.
Introduction
Psoriasis is a common inflammatory disease affecting 3.2% of the US adult population [1] . Systemic treatments such as methotrexate, cyclosporine, and biological agents, i.e. tumor necrosis factor (TNF)-a inhibitors, ustekinumab and newer biologics [2, 3] , have significantly improved burden of disease in patients with moderate to severe psoriasis, and subsequently improving quality of life [4] [5] [6] . A review on psoriasis treatment and malignancy risk was published in 2009 [7] . Since then, therapeutic options have expanded and additional safety data have become available. Herein, we summarize the most recent meta-analyses, randomized controlled trials (RCTs) and prospective cohort studies on Shamir Geller and Haoming Xu contributed equally to this work.
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Baseline Risk of Malignancy in Psoriasis Patients

Systemic Malignancies
Assessing baseline cancer risk in psoriasis is challenging as most studies include both treated and untreated patients. In 2001, Margolis et al. published a landmark study comparing 17,000 psoriasis patients with patients with hypertension, revealing an increased risk ratio of overall malignancy in patients with severe psoriasis (1.78, 95% confidence interval [CI] 1.3 to -2.40) [8] . Most cancers identified in this cohort were lymphoproliferative malignancies and non-melanoma skin cancers (NMSCs) [8] , highlighting the increased risk of malignancy prior to the biologics era. Gelfand et al. conducted a population-based cohort study revealing an increased relative risk (RR) for lymphoma (RR 2.95, 95% CI 1.83-4.76) [9] that persisted after adjusting for age, sex, methotrexate treatment, and development of mycosis fungoides. In a follow-up study, Gelfand et al. reported a positive association between psoriasis and lymphoma (adjusted hazard ratio [aHR] 1.35, 95% CI 1.17-1.55), with strongest association between severe psoriasis with Hodgkin's lymphoma (aHR 3.18, 95% CI 1.01-9.97) and cutaneous T-cell lymphoma (CTCL; aHR 10.75, 95% CI 3.89-29.76) [10] , although the latter association may be a result of misdiagnosing CTCL as psoriasis. Brauchli et al. confirmed an elevated risk of lymphohematopoietic cancer (odds ratio [OR] 2.12, 95% CI 1. 45-3.10 ) and, in a nested case-control analysis, found overall cancer risk was increased in patients who did not receive oral treatment and had disease duration C 2 years (adjusted OR 1.31, 95% CI 1.16-1.48) [11] .
More recently, a prospective, population-based cohort study of 200,000 psoriasis patients revealed minimally increased risk for all cancers, excluding NMSCs (aHR 1.06, 95% CI 1.02-1.09), and for lymphoma (aHR 1.34, 95% CI 1.18-1.51) [12] . In a meta-analysis conducted in 2013, the overall malignancy risk was elevated but was consistent with previous studies (standard incidence ratio [SIR] 1.16, 95% CI 1.07-1.25), with an SIR of 1.4 (95% CI 1.06-1.86) for non-Hodgkin lymphoma (NHL) [13] . A retrospective cohort study in biologic-naive pediatric psoriasis patients found no significant increase in overall cancer risk compared with a matched pediatric population with no psoriasis; however, an increased lymphoma rate was observed when compared with the general population (SIR 5.42, 95% CI 1.62-12.94) [14] . Evidence for an increased risk of solid tumors is inconsistent, but has been previously reported [11] [12] [13] 15] (Table 1) .
Cutaneous Malignancies
Baseline risk of skin cancer in psoriasis patients is difficult to assess due to confounding from phototherapy and immunosuppressive therapy. The rate of NMSC has increased [16] , and is supported by a meta-analysis reporting an SIR of 5.3 for squamous cell carcinoma (SCC; 95% CI 2.63-10.71) and an SIR of 2.00 for basal cell carcinoma (BCC) (95% CI 1.83-2.20), whereas the risk of melanoma was not increased [13] . A large populationbased cohort study confirmed these results, finding an aHR of 1.12 for NMSC (95% CI 1.07-1.16) in the overall psoriasis group, and 1.62 (95% CI 1.16-2.28) in patients with severe psoriasis [12] . A Danish cohort reported modestly increased melanoma risk in patients with mild psoriasis, but not severe psoriasis [17] .
Risk of Cancer with Psoriasis Treatments
Phototherapy
Several studies found oral psoralen and ultraviolet A (PUVA) was associated with an increased risk of skin cancer in a dose-dependent fashion [18] [19] [20] [21] , but not for non-cutaneous malignancies [22] . The risk of NMSC is greatest with [350 treatments, and the risk of genital SCC increased and persisted after the cessation of treatment [23, 24] . In the US, melanoma risk increased with [250 treatments [20] , but was not demonstrated in retrospective European studies with smaller numbers of patients enrolled or shorter follow-up [24] . The risk of Merkel cell carcinoma is also increased [25] .
No increase in skin cancer has been noted with broadband or narrowband-ultraviolet (UV) B, especially in\100 treatments [23, 24, [26] [27] [28] or with bath PUVA [29] . However, in patients treated with broadband UVB with previous PUVA exposure, [300 UVB treatment exposures is associated with a modest but significant increase in NMSCs (SCC incidence rate ratio [IRR] 1.37, 95% CI 1.03-1.83; and BCC IRR 1.45, 95% CI 1.07-1.96) [30] . In summary, PUVA phototherapy increases the risk for skin cancer in a dose-dependent fashion.
Systemic Non-Biologic Therapies
Methotrexate and cyclosporine have been associated with an increased risk of malignancies. The association of these agents and lymphoproliferative disorders, including rare Epstein-Barr virus (EBV)-positive lymphoma, has been aHR adjusted hazard ratio, CI confidence interval, CNS central nervous system, CTCL cutaneous T-cell lymphoma, IRR incidence rate ratio, HR hazard ratio, RR relative risk, SIR standard incidence ratio observed in small case reports and series [31] [32] [33] . While a 30-year follow-up PUVA study found an elevated risk of lymphoma in methotrexate-treated patients (C 36 months), the control was the general population (IRR 4.39, 95% CI 1.59-12.06) [34] . Additionally, recent data showed that low-dose methotrexate monotherapy (B 30 mg/week orally or 17.5-22.5 mg/week subcutaneously) compared with placebo in patients with psoriasis and other diseases revealed no increased malignancy risk [35, 36] . Exposure to methotrexate in patients receiving PUVA was reported to be an independent risk factor for developing SCC (RR 2.1, 95% CI 1.4-2.8), with the potential for metastatic disease [37] . An increased risk for NMSC was reported in rheumatoid arthritis (RA) and psoriatic arthritis patients taking methotrexate and concurrent cyclosporine [38] . In a nationwide Swedish registry, a small risk for melanoma was observed in methotrexate-exposed patients; however, diagnosis, length of exposure and dose were not reported (HR 1.17, 95% CI 1.08-1.26) [39] . The PSOLAR registry, a postmarketing cohort examining the safety of systemic treatments in psoriasis, found no increased risk of malignancy in patients treated with methotrexate (excluding NMSC) [40] . Paul et al. prospectively followed 1252 psoriasis patients treated with cyclosporine for up to 5 years, and reported an increased overall malignancy risk compared with the general population (SIR 2.1). However, the incidence of noncutaneous malignancy did not increase, and the risk was attributed to a sixfold higher incidence of skin malignancies, mostly SCC, affected by longer duration of treatment ([2 years) and previous therapies (PUVA and methotrexate) [41] , confirming the conclusions from a nested cohort showing high SCC risk with cyclosporinetreated patients, particularly after PUVA exposure [42] .
In summary, methotrexate and cyclosporine are generally considered safe; however, there is an elevated risk of SCC associated with cyclosporine and methotrexate, increased by PUVA exposure.
Tumor Necrosis Factor-a Inhibitors
Systemic Malignancies
In 2006, a meta-analysis suggested an increased risk of malignancy with infliximab and adalimumab (OR 3.7, 95% CI 1.0-13.2) analyzing RA RCTs [43] ; however, subsequent data have not confirmed these findings, and an updated meta-analysis including 64 RCTs of RA patients found no increased risk (OR 0.98, 95% CI 0.51-1.9) [44] . Additional meta-analyses pooling together malignancy cases in TNFa inhibitors in rheumatologic, inflammatory bowel disease (IBD) and psoriasis patients failed to reveal increased cancer risk (see Table 2 ). In pooled clinical trial analyses of all indications, anti-TNFa-treated RA patients were found to have a higher incidence of lymphoma [10, [45] [46] [47] compared with the overall population, however there was confounding from increased baseline lymphoma risk in RA patients [46] [47] [48] [49] . In a meta-analysis of Crohn's disease patients, anti-TNFa treatments demonstrated an elevated NHL risk compared with the general population (SIR 3.23, 95% CI 1.5-6.9), but not when compared with immunomodulator-treated patients [50] , suggesting contributory roles of traditional immunosuppressive agents [51] .
The risk of malignancy in anti-TNFa-exposed psoriasis patients examined in a meta-analysis did not find any increased risk (OR 1.26, 95% CI 0.39-4.15) [52] . Pariser et al. studied the risk of malignancy and etanercept therapy in psoriasis patients by an integrated analysis of short-term, placebo-controlled clinical trials, and long-term, uncontrolled, open-label trials, revealing no increase of cancer incidence for etanercept compared with the control group and the overall population (RR 1.11, 95% CI 0.16-12.23, and SIR 1.2, 95% CI 0.8-1.6, respectively). The risk did not increase with increasing doses or exposures [53] . The PSOLAR registry examined the safety of anti-TNFa agents and ustekinumab and reported that long-term (C 12 months) anti-TNFa therapy, but not short-term treatment, may increase malignancy risk, excluding NMSC (OR 1.54, 95% CI 1.10-2.15); however, analyses performed for individual anti-TNFa agents were not statistically significant, and a monotherapy analysis that excluded cases with multiple exposures to study agents observed no elevated risk [40] . The OBSERVE-5, a 5-year surveillance registry, studied 'real-world' etanercept use in psoriasis patients and found cumulative incidences of 3.2% for malignancies, excluding NMSC (95% CI 2.3-4.1%) and 0.1% for lymphoma (95% CI 0.0-0.3%), which were not higher than expected (SIR \1) [54] . The safety of adalimumab in psoriasis patients was demonstrated by the initial 7-year results of the ESPRIT registry [55] . Studying a large healthcare delivery system database, systemic malignancy and lymphoma rates were not increased for biologics in psoriasis patients [56] .
Non-Melanoma Skin Cancer
An association between biologics and NMSC has been reported in RA and IBD patients [57] [58] [59] ; however, several meta-analyses found no increased risk for NMSC [44, 52, 53, [60] [61] [62] . Additional studies have shown that anti-TNFa-treated patients were at increased risk for SCC but not BCC [45, 63] . Asgari et al. recently reported that NMSC rates were 42% higher among psoriasis patients ever exposed to biologics (HR 1.42, 95% CI 1.12-1.80), largely driven by SCC risk (HR 1.81, 95% CI, 1.23-2.67) and not BCC [56] . A comparison of NMSC risk in antiTNFa-exposed psoriasis versus RA patients showed a significantly higher risk in psoriasis patients (HR 6.0, 95% CI 1.6-22.4) [64] , highlighting contributory roles of prior psoriasis therapies such as phototherapy. Prior or concurrent methotrexate treatment was reported to increase the risk of NMSC in RA [65, 66] .
Melanoma
A meta-analysis investigating the risk of malignant melanoma and TNFa inhibitors found a non-significantly elevated risk (RR 1.79, 95% CI 0.92-2.67) [58] . A recent pooled analysis of 11 European registries that included over 48,000 anti-TNFa-treated RA patients did not reveal any elevated risk [67] ; however, a meta-analysis of four studies found an increased risk of melanoma in RA patients treated with anti-TNFa therapy compared with non-biologics (pooled effect estimate 1.60, 95% CI 1.16-2.19) [68] . Raaschou et al. found an increased risk of invasive melanoma in RA patients treated with anti-TNFa therapy (HR 1.5, 95% CI 1.0-2.2), but not melanoma in situ [69] . Furthermore, an elevated risk of melanoma was also reported in IBD patients treated with TNFa inhibitors (OR 1.88, 95% CI 1.08-3.29) [70] . A retrospective, singlecenter study on anti-TNFa-treated patients for any indication reported an increased risk of developing melanoma (RR 1.75, 95% CI 1.25-2.43) [71] . Safety data from clinical studies showed increased melanoma incidence in adalimumab-treated psoriasis patients compared with the overall population (SIR 3.67 [72] -4.37 [47] , 95% CI 1.47-7.57 and 1.89-8.61, respectively); however, in a large cohort, the risk of melanoma was similar for psoriasis patients treated with biologic and non-biologic therapies [56] . In summary, numerous recent meta-analyses, and observational and cohort studies found no significantly increased risk of systemic malignancies, including lymphoma for anti-TNFa in psoriasis, providing reassurance regarding the widespread use of these agents. An increased risk of SCC has been confirmed by several studies, but there is conflicting evidence regarding the risk for melanoma.
New Biologics and Small Molecule Inhibitors
The emergence of targeted biologics for psoriasis in recent years has greatly expanded the spectrum of therapeutic options. Current biologic targets of interest in psoriasis include interleukin (IL)-12, IL-23, IL-17, Janus kinase (JAK), and phosphodiesterase-4. IL-12 has demonstrated anti-tumor effects in mouse models via enhancement of both innate resistance and adaptive immunity [73] ; IL-23 has predominantly anti-tumor effects in mouse models through interferon-c and CD8? T-cell-dependent pathways [74] ; and IL-17 is a proinflammatory cytokine that produces anti-tumor effects in immune-competent mice, but protumor effects in immune-deficient mice [74] . The JAK-STAT pathway is responsible for the transduction of a myriad of extracellular signals, and dysregulation of this pathway has been linked to a variety of hematological malignancies [75] . Phosphodiesterase-4 has been shown to promote angiogenesis in both lung cancer and lymphoma models through elevation of cyclic adenosine monophosphate [76, 77] .
As with all new drugs, the robustness of safety profiles obtained from clinical trials data should not be broadly extrapolated as they have yet to be validated in a real-world setting. Table 3 summarizes the incidence rates of malignancy for these newer treatments, including biologics targeting IL-12/23 (ustekinumab) [78] [79] [80] [81] [82] [83] , IL-23 (guselkumab) [84, 85] , IL-17 (ixekizumab, secukinumab) [86] [87] [88] , and small molecule inhibitors of JAK (tofacitinib) [89] and phosphodiesterase-4 (apremilast) [90] [91] [92] . AS ankylosing spondylitis, CD Crohn's disease, CI confidence interval, HR hazard ratio, IBD inflammatory bowel disease, NMSC non-melanoma skin cancer, OR odds ratio, Pso psoriasis, PsA psoriatic arthritis, RA rheumatoid arthritis, RR relative risk Malignancy incidence rates for these therapies are less than, or comparable to, those seen in the psoriasis population (1.14 per 100 person-years) and general population (0.95 per 100 person-years) [16] , but currently available evidence is not sufficient to draw conclusions on their safety. Long-term studies focused on safety surveillance are still lacking for these agents, especially ixekizumab, secukinumab, and apremilast, as well as data for their use in cancer patients and survivors.
Psoriasis Treatments and Malignancy Risk in Cancer Patients and Survivors
Evidence-based data on the association between psoriasis systemic treatments and cancer recurrence is limited since patients with a history of malignancies are usually excluded from participating in clinical trials and dermatologists are hesitant to initiate immunosuppressive agents in cancer survivors. Moreover, psoriasis flares have been noted with the advent of the new immune checkpoint inhibitors for malignant melanoma, such as ipilimumab [93] , nivolumab and pembrolizumab [94] , making treatment decisions challenging (Fig. 1 ).
Systemic Malignancies
A recent meta-analysis of cohort, case-control, and caseseries studies, including 11,702 cancer survivors with RA, IBD and psoriasis treated with anti-TNFa agents, immunomodulator therapies (methotrexate or thiopurines) or no immunosuppression therapy, aimed to investigate cancer incidences [95] . Follow-up was 21-102 months, with a median of 6 years between the index cancer and immunosuppression initiation. Cancer recurrence incidences were similar for anti-TNFs, immunosuppression therapy and no immunosuppression (33.8, 36.2 and 37.5 cancer recurrences or new primary cancer cases per 1000 patient-years, respectively). A non-significant higher incidence rate was revealed for combination immunosuppression therapy (54.5/1000 person-years; p = 0.47); similar non-significant differences were identified when excluding CI confidence interval, IL interleukin, IR incidence rates, JAK Janus kinase, LTEs long-term extension studies, NMSC non-melanoma skin cancer, PDE-4 phosphodiesterase-4, PY patient-years skin cancers. Additional subanalyses were performed, i.e. new cancer and recurrent cancer incidences, analyses by inflammatory disease and comparing thiopurines versus methotrexate, and no statistically significant differences between the groups were reported [95] . A recent study of the British RA registry confirmed no increased risk of malignancy in cancer survivors with RA treated with TNFa inhibitors compared with non-biologics after a median follow-up period of 6.8 years [96] .
Cutaneous Malignancies
A retrospective study of RA and IBD patients with a history of NMSC showed methotrexate use was associated with an increased risk of a second NMSC in RA (HR 1.60, 95% CI 1.08-2.37). The addition of an anti-TNFa agent increased the risk, as did longer methotrexate exposure [66] . No increased risk for a consecutive primary melanoma was found in patients with methotrexate exposure [97] . Furthermore, a non-significant increased rate of a second melanoma was reported in RA patients treated with anti-TNFa agents compared with non-biologics (HR 3.2, 95% CI 0.8-13.1) [69, 98] . Notably, the use of infliximab and adalimumab for ipilimumab-induced colitis in advanced-stage melanoma patients has been reported to have no effect on worsening prognosis and survival [99] .
In the PSOLAR study, 3.8% of psoriasis patients had a history of systemic malignancy, while 6.2% had a history of skin cancer. In this cohort, a history of malignancy was reported to be associated with higher cancer rates (HR 2.64, 95% CI 1.88-3.69) [83] ; however, malignancy recurrence rates were comparable in patients who were treated with biologic (anti-TNFa agents or ustekinumab) or non-biologic therapies (2.48 vs. 3.78 per 100 person-years, respectively) [100] .
In summary, the risk of new or recurrent systemic malignancies is similar between biologic and non-biologic treatments. The risk of additional NMSCs in patients with a history of NMSC may be increased; however, data regarding additional primary melanomas and melanoma recurrence are inconclusive in melanoma survivors.
Conclusion
Based on recent studies with a high level of evidence, we conclude that there is little evidence of an association between non-cutaneous malignancies and the reviewed psoriasis treatments, regardless of a history of prior cancer. There are conflicting data regarding the risk of melanoma in patients treated with anti-TNFa agents. In addition, there is an elevated risk of SCC for both anti-TNFa agents and non-biologic therapies that increased with PUVA exposure and/or immunosuppressive treatments. Our conclusions are based on meta-analyses from the rheumatology, gastroenterology, and dermatology literature that compared treated patients with control patients rather than the general population, thereby eliminating possible confounding from baseline malignancy risk of the inflammatory disease [101] . Results from meta-analyses are limited by relatively Fig. 1 Immunotherapy-induced psoriasis. A 54-year-old female with no prior history of psoriasis, developed numerous scaly erythematous papules and plaques on her limbs, including the palms and the trunk. The rash appeared after starting therapy with nivolumab (anti-PD-1) and varlilumab (anti-CD27) therapy for recurrent glioblastoma. Histology of the scaly plaque on the elbow confirmed the diagnosis of psoriasis short exposure and follow-up periods, but large observational cohort studies confirm these findings. New or recurrent cancer incidence rates are modest and should be weighed against the advantage of controlling disease in psoriasis patients. The newer biologic and non-biologic agents seem promising and effective, however additional studies are needed to evaluate malignancy risk in these agents.
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